Abstract
The endogenous steroid 2-methoxyestradiol (2-ME) is a metabolite of 17-estradiol and its biosynthesis is well established. Moreover, 2-ME is also biosynthesized from estrone. For several years, 2-ME was perceived as an inactive metabolite devoid of any interesting biological activities. Since the late 1980s, a number of biological and pharmacological studies have revealed that 2-ME possesses interesting anti-cancer effects without any undesirable estrogen activity. In particular, the anti-vascular effects and anti-angiogenic activities that 2-ME exhibit, are of great interest and importance, in view of the development of new anti-cancer drugs based on 2-ME. Several clinical trial development programs have been initiated using the steroid 2-ME. In addition, based on the many pharmacological activities reported for 2-ME, but also due to the general interest in total and semi-synthesis of endogenous steroids, several research groups working with organic synthesis have prepared this steroid. Herein, the anti-cancer effects, the results from the clinical trial development programs and the synthetic studies towards 2-ME, are reviewed.
Keywords: Steroid, 2-methoxyestradiol, anti-cancer effects, anti-vascular effects, anti-angiogenic activities, tubulin inhibition, clinical trials, total synthesis, regioselectivity.
Current Pharmaceutical Design
Title:Synthesis and Pharmacological Effects of the Anti-Cancer Agent 2-Methoxyestradiol
Volume: 21 Issue: 38
Author(s): Eirik Johansson Solum, Oyvind W. Akselsen, Anders Vik and Trond Vidar Hansen
Affiliation:
Keywords: Steroid, 2-methoxyestradiol, anti-cancer effects, anti-vascular effects, anti-angiogenic activities, tubulin inhibition, clinical trials, total synthesis, regioselectivity.
Abstract: The endogenous steroid 2-methoxyestradiol (2-ME) is a metabolite of 17-estradiol and its biosynthesis is well established. Moreover, 2-ME is also biosynthesized from estrone. For several years, 2-ME was perceived as an inactive metabolite devoid of any interesting biological activities. Since the late 1980s, a number of biological and pharmacological studies have revealed that 2-ME possesses interesting anti-cancer effects without any undesirable estrogen activity. In particular, the anti-vascular effects and anti-angiogenic activities that 2-ME exhibit, are of great interest and importance, in view of the development of new anti-cancer drugs based on 2-ME. Several clinical trial development programs have been initiated using the steroid 2-ME. In addition, based on the many pharmacological activities reported for 2-ME, but also due to the general interest in total and semi-synthesis of endogenous steroids, several research groups working with organic synthesis have prepared this steroid. Herein, the anti-cancer effects, the results from the clinical trial development programs and the synthetic studies towards 2-ME, are reviewed.
Export Options
About this article
Cite this article as:
Solum Johansson Eirik, Akselsen W. Oyvind, Vik Anders and Hansen Vidar Trond, Synthesis and Pharmacological Effects of the Anti-Cancer Agent 2-Methoxyestradiol, Current Pharmaceutical Design 2015; 21 (38) . https://dx.doi.org/10.2174/1381612821666151002112511
DOI https://dx.doi.org/10.2174/1381612821666151002112511 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Modifiers of Risk in BRCA1/2 Mutation Carriers
Current Women`s Health Reviews PARP1: A Promising Target for the Development of PARP1-based Candidates for Anticancer Intervention
Current Medicinal Chemistry Histopathological Determinants of Tumor Resistance: A Special Look to the Immunohistochemical Expression of Carbonic Anhydrase IX in Human Cancers
Current Medicinal Chemistry Potential Application of Dietary Polyphenols from Red Wine to Attaining Healthy Ageing
Current Topics in Medicinal Chemistry Neuroinflammation, Oxidative Stress and the Pathogenesis of Alzheimers Disease
Current Pharmaceutical Design Modulation of the Endocannabinoid System by Lipid Rafts
Current Medicinal Chemistry Inhibitors of Steroidal Cytochrome P450 Enzymes as Targets for Drug Development
Recent Patents on Anti-Cancer Drug Discovery Liver-Directed Regional Therapy in the Multi-Disciplinary Management of Hepatocellular Cancer
Current Cancer Therapy Reviews Serotonin and Human Cognitive Performance
Current Pharmaceutical Design Novel Next-Generation Sequencing and Networks-Based Therapeutic Targets: Realistic and More Effective Drug Design and Discovery
Current Pharmaceutical Design Design and Development of Nanoemulsion Systems Containing Interferon Gamma
Protein & Peptide Letters Cardioprotective Effects of the Polyphenol Hydroxytyrosol from Olive Oil
Current Drug Targets Edema-mass Ratio Based On Magnetic Resonance Imaging As A Preoperative Diagnostic Factor For Posterior Fossa Metastasis
Current Medical Imaging Signal Transduction Therapy Targeting Apoptosis Pathways in Cancers
Current Signal Transduction Therapy Role of Retinoids, Rexinoids and Thyroid Hormone in the Expression of Cytochrome P450 Enzymes
Current Drug Metabolism P-glycoprotein as a Drug Target in the Treatment of Multidrug Resistant Cancer
Current Drug Targets Understanding the Potential Role and Delivery Approaches of Nitric Oxide in Chronic Wound Healing Management
Current Pharmaceutical Design Ribonucleotide Reductase: A Mechanistic Portrait of Substrate Analogues Inhibitors
Current Medicinal Chemistry Xenosensors CAR and PXR at Work: Impact on Statin Metabolism
Current Drug Metabolism Targeting of Cancer-Related Proteins with PNA Oligomers
Current Cancer Drug Targets